Omnicare buys RxCrossroads for $235M

Omnicare has inked a deal to by specialty drug supplier RxCrossroads for $235 million. The buyout is seen as a strategic fit for Omnicare, which supplies drugs to seniors in elderly care facilities. Omnicare says that once the acquisition is complete, they'll be able to offer a full range of services to pharmaceutical and biotech companies throughout the country. RxCrossroads distributes high-cost biotech drugs for the chronically ill. The company reported $46 million in revenue. Omnicare, which has been trying to buy NeighborCare, reported more than $4 billion in revenue last year.

- read this story from the AP for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.